Scarica l'app Stockscreener
2.20
8.64%
0.175
Dopo l'orario di chiusura:
2.17
-0.03
-1.36%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Pds Biotechnology Corporation Borsa (PDSB) Ultime notizie
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround - Yahoo Finance
PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright - Defense World
PDS Biotechnology's (PDSB) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
PDS Biotechnology to Present at H.C. Wainwright Bioconnect Virtual Conference - StockTitan
PDS Biotechnology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2024 Earnings Call Transcript - Insider Monkey
PDS Biotechnology Corporation (PDSB) Quarterly 10-Q Report - Quartzy
PDS Biotechnology: Q3 Earnings Snapshot - New Haven Register
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... By GuruFocus - Investing.com Canada
PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks
Earnings call: PDS Biotech reports progress in HPV cancer trials By Investing.com - Investing.com Canada
PDSB stock touches 52-week low at $2.21 amid market challenges - Investing.com India
PDS Biotechnology Shares Down 18% After Phase 3 Trial Modifications - MarketWatch
PDS Biotechnology Corporation Provides Clinical Programs Update - Marketscreener.com
U.S. Stock market: Nuvectis Pharma saw a sharp decline of 53.89% while AgEagle Aerial Systems surged by 133.74% in early trading - Business Upturn
PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results - The Manila Times
PDS Biotech Reports $10.7M Q3 Loss, Streamlines Phase 3 Trial Design | PDSB Stock News - StockTitan
PDS Biotechnology (PDSB) to Release Earnings on Thursday - Defense World
PDS Biotechnology (NASDAQ:PDSB) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
PDS Biotechnology (PDSB) Set to Announce Quarterly Earnings on Thursday - MarketBeat
PDS Biotech: Interview With President And CEO Frank Bedu-Addo About The Immunotherapy Company - Pulse 2.0
PDS Biotechnology Sets Q3 Earnings Call: Clinical Updates Expected Nov 14 | PDSB Stock News - StockTitan
Contrasting Semiconductor Manufacturing International (OTCMKTS:SMICY) & POET Technologies (NASDAQ:POET) - Defense World
StockNews.com Initiates Coverage on Ark Restaurants (NASDAQ:ARKR) - Defense World
Jones Soda Announces Departure of President and CEO, David Knight, and Appointment of Interim CEO, Paul Norman - Defense World
Mastech Digital (NYSE:MHH) Coverage Initiated by Analysts at StockNews.com - Defense World
PDS Biotechnology Co. (NASDAQ:PDSB) Receives $14.25 Consensus Price Target from Analysts - MarketBeat
Head-To-Head Analysis: Edison International (NYSE:EIX) and AltC Acquisition (NYSE:ALCC) - Defense World
FS KKR Capital Corp. (NYSE:FSK) Given Consensus Rating of “Hold” by Brokerages - Defense World
StockNews.com Begins Coverage on TRX Gold (NYSE:TRX) - Defense World
Mastech Digital (NYSE:MHH) Now Covered by Analysts at StockNews.com - Defense World
Bowhead Specialty (NYSE:BOW) versus Horace Mann Educators (NYSE:HMN) Critical Survey - Defense World
Zacks Research Issues Negative Estimate for CSX Earnings - Defense World
Hillman Solutions (HLMN) to Announce Quarterly Earnings on Tuesday - Defense World
Evolv Technology Holdings CEO terminated, replaced by Michael Ellenbogen as Interim CEO - Defense World
Chase (NYSE:CCF) Now Covered by Analysts at StockNews.com - Defense World
PDS Biotechnology (NASDAQ:PDSB) Stock Rating Upgraded by StockNews.com - MarketBeat
HC Wainwright Reaffirms Buy Rating for PDS Biotechnology (NASDAQ:PDSB) - MarketBeat
Is There More Room To Run For This Immunotherapy Company Stock After Hitting New High? - RTTNews
PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine - The Manila Times
Critical Review: PDS Biotechnology (NASDAQ:PDSB) & InflaRx (NASDAQ:IFRX) - Defense World
NY Biopharma Shares Promising Clinical Data - Streetwise Reports
Data Readouts At ASCO (MRUS, ORIC, CGEN, PDSB...) - RTTNews
H.C. Wainwright & Co. Shares Buy Rating on Biotech Co. - Streetwise Reports
PDS Biotechnology Co. (NASDAQ:PDSB) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Europe Aneurysmal Subarachnoid Hemorrhage Drugs Market Size, Spotlight on Future Potentials (2024-2034) - IndiaPolitics.com
CD47 Inhibitors Market Projected to Grow Significantly with Emerging Cancer Therapies by 2034 | DelveInsight - The Malaysian Reserve
Mass. Biotech Receives FDA Approval - Streetwise Reports
PDS Biotechnology Corporation: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):